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Introduction: D-dimer is a degradation product of cross-linked fibrin. We hypothe-
sized that hemorrhagic pleural effusions would have greater D-dimer levels than
non-hemorrhagic pleural effusions, and that persistently bloody effusions would be
distinguishable from thoracentesis-induced bloody effusions by the D-dimer level.
Methods: Forty pleural effusions were studied. D-dimer levels (measured by ELISA),
red blood cell (RBC) count, white blood cell (WBC) count, lactate dehydrogenase
(LDH), and protein level was measured for each effusion. Ten effusions, five non-
bloody, and five bloody were studied for each of the following disease states:
parapneumonic effusion, congestive heart failure, post-coronary artery bypass
grafting, and lung cancer.
Results: No significant difference of the D-dimer level was noted between bloody
and non-bloody effusions of different disease states (P ¼ 0:286). There was no
significant difference in the median D-dimer levels between all the bloody and all
the non-bloody effusions (P ¼ 0:88). There was no significant difference (P ¼ 0:51) in
D-dimer levels between five diseases groups when the bloody and non-bloody fluids
were combined. The D-dimer levels did not correlate with the RBC count (r ¼ 0:11,
P ¼ 0:48), WBC count (r ¼ 0:13, P ¼ 0:53), LDH (r ¼ 0:01, P ¼ 0:93), or protein levels
(r ¼ 0:01, P ¼ 0:93) in any of the groups.
Conclusion: Measurement of pleural fluid D-dimer levels does not distinguish
persistently bloody effusions from non-bloody effusions, and does not aid in
narrowing the differential diagnosis of an effusion.
& 2005 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserv
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D-dimer is a degradation product of cross-linked
fibrin. It has been suggested that the D-dimer assayed.
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to accurately differentiate subarachnoid hemor-
rhage from traumatic lumbar puncture in that
the D-dimer levels are higher with subarachnoid
hemorrhage.1 Therefore, we hypothesized that
hemorrhagic pleural effusions would have
higher D-dimer levels than non-hemorrhagic
pleural effusions, and that persistently bloody
effusions would be distinguishable from thoracent-
esis-induced bloody effusions by the D-dimer
level.Methods
Saint Thomas Hospital is a tertiary-care medical
center. Since September 1, 1997, we have main-
tained a database on all patients who undergo
ultrasonically guided thoracentesis and who sign an
informed consent approved by the Institutional
Review Board. Every patient (both outpatients and
inpatients) who undergoes ultrasound-assisted
thoracentesis in Saint Thomas Hospital and signs
the consent form is prospectively entered. We
conducted a retrospective pilot study to examine
whether hemorrhagic pleural effusions have higher
D-dimer levels than non-hemorrhagic pleural effu-
sions, and whether persistently bloody effusions
are distinguishable from thoracentesis-induced
bloody effusions by the D-dimer level. The etiology
of the pleural effusion, the lactate dehydrogenase
(LDH) and total protein levels, red blood cell (RBC),
and white blood cell (WBC) counts of the pleural
fluid were recorded. Pleural fluids from 40 patients
were studied. The pleural samples were collected
between January 2003 and January 2004. We
selected pleural fluids such that we would have
10 pleural fluids, five non-bloody, and five bloody
from each of the following disease states: para-
pneumonic effusion, congestive heart failure,
post-coronary artery bypass grafting (CABG), and
malignant effusion due to lung cancer. A bloody
pleural fluid was identified by its gross appearance
as recorded by the technician. A pleural effusion
was said to be caused by congestive heart failure if
the patient had symptoms and signs of congestive
heart failure that improved with appropriate
therapy. A pleural effusion was said to be malignant
if the patient had either a pleural fluid cytologic
examination or a pleural biopsy specimen that
was positive for malignancy, or if the patient had
known metastatic malignancy with no other ex-
planation for the pleural effusion. A pleural
effusion was labeled post-CABG when it occurred
within the first few months after CABG and had noother obvious explanation (e.g. congestive heart
failure, chylothorax, or infection). A parapneumo-
nic effusion was an effusion associated with
bacterial pneumonia, lung abscess, or bronchiec-
tasis. The samples for the D-dimer determinations
were collected in vacutainer tubes containing
3.8% citrate, centrifuged (2500g for 15min), and
the supernatants were frozen at 0 1C D-dimer
levels were measured by enzyme-linked immuno-
sorbent assay (ELISA) (TintElize, Biopool, Sweden).
The normal value of the TintElize D-dimer assay is
39 ng/mL with a standard deviation of 12.2
The TintElize test measures D-dimer antigen in
the range 75–5000 ng/mL. The Biopool TintElize
D-dimer utilizes the double antibody principle.
Plasma sample or standard containing D-dimer is
added to a microtest well, which is coated with a
monoclonal antibody, MA-8D3, against D-dimer.
After an incubation sufficient to allow 485% of
the D-dimer to bind to the coat antibodies,7
HRP labelled Fab fragments of anti D-dimer IgG
are added. These are allowed to react with
the adsorbed D-dimer. The wells are emptied
and washed to remove unbound conjugate
after which peroxidase substrate (OPD/H2O2) is
added. The amount of yellow color developed is
directly proportional to the amount of D-dimer
present in the sample. All the samples were
stored at 70 1C for less than 1 year. RBC counts,
WBC counts, LDH (the upper limit of LDH in the
present study’s laboratory was 243 UAL ), and
protein level in pleural effusions were measured
when samples were first collected. The RBC and
WBC counts were measured using an automated
cell counter (Coulter Electronics, Lutton, UK).
Protein and LDH levels were determined with
an automated analyzer (Johnson & Johnson,
Rochester, NY, USA).Statistical methods
All data are expressed as mean7SD unless
otherwise stated. Because the pleural fluid
D-dimer, protein, LDH, RBC, and WBC counts
were not normally distributed, Kruskal–Wallis one-
way analysis of variance on ranks was used for
comparing the D-dimer levels among groups, and
Dunn’s method was used to perform multiple
comparison procedures. Correlations were ana-
lyzed with the Spearman rank order correlation
since the data was not normally distributed. Data
were analyzed using SigmaStat v2.03 statistical
software package (Jandel Scientific, San Rafael,
CA, USA). Differences in results were considered
significant when Po0:05.
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D-dimer levels were at detectable levels in all the
pleural fluids (ranged between 357 and 3179ng/mL)
(Fig. 1). One-way analysis of variance showed that
the D-dimer levels between the eight groups were
not significantly different (P ¼ 0:286). Comparison
of the D-dimer levels in each group between bloody
vs. non-bloody effusions by t-test (Table 1) showed
a significant difference in only malignant effusion
group (P ¼ 0:002). However, contrary to our hy-
pothesis, non-bloody malignant effusions had high-
er D-dimer levels than bloody malignant effusions.
There was no significant difference in the median
D-dimer levels between all the bloody and all the
non-bloody effusions (P ¼ 0:88).
There was no significant difference (P ¼ 0:51) in
D-dimer levels by one-way analysis of varianceGroups
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Figure 1 Pleural D-dimer levels in different groups.
Table 1 Comparison between the pleural fluid characte
Groups n,5 Variables
D-dimer (ng/mL) RBCC,  103 (mL)
PPE/NB 2539 (2108–2676) 940 (526–3237)
PPE/B 2441 (2120–3023) 52,500 (28,000–63,375)
CHF-NB 2851 (2079–2956) 175 (18.2–1162)
CHF-B 2694 (2566–2836) 2700 (1481–415,000)
CABG-NB 2857 (2628–2944) 945 (416–3506)
CABG-B 2786 (2548–3080) 150,000 (65,625–251,000
LC-NB 2979 (2753–3035) 525 (52.5–21,375)
LC-B 2156 (1853–2418) 56,000 (4550–116,062)
P-values 0.286 0.004
Data are presented as median (quartile boundaries).
NB: non-bloody; B: bloody; PPE: parapneumonic effusion; CHF: c
lung cancer.between five diseases groups when the bloody and
non-bloody fluids were combined.
We analyzed the data for all 40 patients to
determine whether there was any relationship
between the pleural fluid D-dimer levels and other
characteristics of the pleural fluid. There was no
correlation between D-dimer levels and the RBC
counts (r ¼ 0:11, P ¼ 0:48), WBC counts (r ¼ 0:13,
P ¼ 0:53), LDH (r ¼ 0:01, P ¼ 0:93), or protein
levels (r ¼ 0:01, P ¼ 0:93).Discussion
When blood enters the pleural space, the coagula-
tion process is activated and the blood clots.
Subsequently there is a fibrinolytic reaction due
to the large amounts of plasminogen and plasmino-
gen activators present in the pleural space.3 The
main plasminogen activators in the pleural space
are tissue plasminogen activator and urokinase
plasminogen activator. The plasminogen activators
convert the inactive zymogen plasminogen into
active plasmin, which, in turn, enzymatically
breaks down fibrin.4–6 D-dimer is the primary
degradation product of cross-linked fibrin and
therefore serves as a direct marker of ongoing
coagulation with fibrinolysis. Increased levels of
D-dimer are found in conditions that result in
activation of the fibrinolytic system.7
Lang and coworkers reported that D-dimer levels
in cerebral spinal fluid samples accurately differ-
entiated subarachnoid hemorrhage from traumatic
lumbar puncture.1 In their study, the D-dimer assay
was positive in all six patients with subarachnoid
hemorrhage whereas the D-dimer assay wasristics from the eight groups.
WBC,  103 (mL) TP (g/dL) LDH (IU/L)
2750 (830–6831) 3.1 (2.8–3.6) 442 (108–667)
2000 (1562–3500) 4.3 (3.3–5.2) 182 (102–483)
90 (48.5–281) 3 (2.6–3.5) 86 (65.5–119)
1000 (325–3000) 3.2 (3–3.2) 160 (123–206)
1285 (1122–2856) 4 (3.1–4.4) 136 (110–198)
) 1000 (911–3875) 2.9 (2.6–4.3) 357 (210–687)
530 (331–1125) 4.1 (3.7–4.75) 148 (126–289)
400 (275–562) 4.1 (4.1–4.9) 251 (187–418)
0.003 0.034 0.05
ardiac heart failure; CABG: post-cardiac by-pass surgery; LC:
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hemorrhagic cerebral spinal fluid secondary to
traumatic lumbar puncture and in 20 patients with
normal cerebral spinal fluid.
We hypothesized that hemorrhagic pleural effu-
sions would have higher D-dimer levels than non-
hemorrhagic pleural effusions, and that persis-
tently bloody effusions would be distinguishable
from thoracentesis-induced bloody effusions by the
D-dimer level. However, this study showed that the
D-dimer levels are not significantly different
between bloody and non-bloody effusions from
patients with parapneumonic effusion, congestive
heart failure, post-cardiac bypass surgery, and lung
cancer. The only significant difference observed
was in the lung cancer group. However, the mean
D-dimer level in non-bloody malignant effusions
was higher than that in the bloody effusions, which
was opposite to our hypothesis. It has been
previously suggested that there is hyperfibrinolysis
in malignant pleural effusions, and this is mainly
due to excessive concentrations of tissue plasmino-
gen activator and urokinase plasminogen activa-
tor.8 Nevertheless, the D-dimer levels were not
higher in malignant than in benign effusions.
Only two previous investigations have evaluated
the role of D-dimer measurement in the differential
diagnosis of pleural effusions. Lu et al.9 reported
that D-dimer levels measured by ELISA were
significantly higher in pleural fluid from patients
with tuberculous pleuritis and empyema than those
in pleural fluid from patients with malignant
pleural effusions. Moreover, D-dimer levels were
positively correlated with LDH in pleural fluid
(r ¼ 0:4168, Po0:01). In contrast, Philip-Joet
et al.10 reported no significant difference in the
mean pleural fluid D-dimer levels, between differ-
ent etiologies including 10 empyema, nine tuber-
culosis, 31 cancer, seven cardiac failure, and three
patients with undetermined etiology. The present
study is in agreement with that of Philip-Joet
et al.10 and although the numbers of patients were
small in each disease category, there was no hint
that the D-dimer levels would ever be useful in the
differential diagnosis of pleural effusions. These
data including that of the present study suggest
that pleural D-dimer levels may depend on various
other factors such as inflammation. It seems like
the degree of inflammation has more effect on the
pleural effusion D-dimer levels than ongoing bleed-
ing or the clotting balance. Therefore, we were not
able to prove our hypothesis that bloody effusions
would have higher D-dimer levels than non-bloody
effusions.
In the present study, the D-dimer levels were
higher than the normal upper limit for serum in allpleural effusions suggesting strong fibrinolytic
activity. Abnormal fibrinolysis occurs when the
balance between activators and inhibitors is dis-
turbed. Increased production of plasminogen acti-
vator inhibitors is partially responsible for fibrin
deposition within the pleural space of patients with
parapneumonic effusions,11,12 whereas overexpres-
sion of plasminogen activators leads to excessive
fibrinolysis that is observed in patients with
malignant effusions.4,13 Alema´n et al.14 found that
plasminogen activity and the levels of plasminogen
activators were significantly lower in malignant
effusions than other types of effusions. The con-
centrations of plasminogen activator inhibitor 2 in
empyema and complicated parapneumonic effu-
sions exceeded those in tuberculous effusions. In
addition, the pleural fluid levels of tissue plasmino-
gen activators were higher in patients with tuber-
culous or malignant effusions than other patients.
Although existent data support the importance of
pleural injury as the cause of increased intrapleural
fibrinolytic activity in exudative pleural effusions,
the mechanism to explain the increased pleural
D-dimer levels in patients with heart failure
remains unclear.
There have been several previous studies that
measured D-dimer levels in pleural fluid in con-
junction with many other measurements and
mainly as a marker of fibrinolysis or inflamma-
tion.15,16 Agrenius et al.15 found that D-dimer levels
were in higher than normal concentrations in
chronic malignant effusions (62.7725.5 mg/ml),
and decreased 6 h after the intrapleural instillation
of quinacrine (12.277.9 mg/ml). They suggested
that an activated fibrinolytic system with a chronic
malignant pleural effusion is partially deacti-
vated after intrapleural quinacrine instillation.
Rodriguez-Panadero et al.16 reported similar find-
ings in a study designed to show that impairment in
fibrin formation or increased intrapleural fibrino-
lysis would lead to failure of pleurodesis. In their
study, fibrinolytic activity (as assessed by D-dimer
levels) showed a clear decline 24 h after talc
poudrage in patients with a good pleurodesis
outcome in contrast to those with a poor outcome
and to those in the control group who had no signi-
ficant change in the D-dimer levels with time.16
In conclusion the present study demonstrates
that blood in pleural fluid is not associated with a
significant increase in the pleural fluid D-dimer
levels. Measurement of pleural fluid D-dimer
levels does not distinguish persistently bloody
effusions from non-bloody effusions. Moreover,
measurement of pleural fluid D-dimer levels
does not aid in narrowing the differential diagnosis
of an effusion.
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